2. Academic Validation
  3. Development of UM-200: A Novel Alkyne Amide-Based Inhibitor of the cGAS-STING Pathway

Development of UM-200: A Novel Alkyne Amide-Based Inhibitor of the cGAS-STING Pathway

  • J Med Chem. 2026 Apr 9;69(7):8561-8582. doi: 10.1021/acs.jmedchem.6c00237.
Leonard Barasa 1 2,  Leo DeOrsey 1 2,  Maeve D O'Reilly 1 2,  Shruti Choudhary 1 2,  Sara E Cahill 3,  Anukriti Mathur 3,  Akumalla Allabaji 4,  Shreekrishna Nellikkalaya 4,  Sourav Paul 4,  Srinivasa Rao Vidadala 4,  Sujit Kumar Sarkar 4,  Muruganantham Rajendran 4,  Santoshkumar N Patil 4,  Harikesh Kalonia 4,  Jeffrey Hale 5,  Fiachra Humphries 3,  Katherine A Fitzgerald 3,  Paul R Thompson 1 2
Affiliations

Affiliations

  • 1 Program in Chemical Biology, University of Massachusetts Chan Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States.
  • 2 Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States.
  • 3 Division of Innate Immunity, Department of Medicine, University of Massachusetts Chan Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States.
  • 4 Syngene International Ltd., Bommasandra-Jigani Link Road, Biocon Park, Bangalore-560100, India.
  • 5 Jeffrey Hale, Hale MedChem Advisors LLC, 233 Hazel Avenue, Westfield, New Jersey 07090, United States.
PMID: 41866990 DOI: 10.1021/acs.jmedchem.6c00237
Abstract

In response to double stranded DNA (dsDNA), the cGAS-STING pathway activates the innate immune response. While beneficial for detecting invading bacteria and viruses, overactivation of this pathway is associated with the development of several inflammatory and autoimmune diseases, making STING an attractive therapeutic target. Previously, we reported STING inhibitors that employ a nitrofuran warhead; these compounds covalently modify STING and prevent its oligomerization. Herein we describe our efforts to identify alternative electrophilic warheads using UM-001 as a starting scaffold. These efforts led to UM-200, a next-generation inhibitor featuring an alkyne amide warhead. UM-200 potently suppresses STING signaling in murine and human systems, retains activity against the prevalent human STING variant (R232), and effectively inhibits pathway activation in primary human CD14+ monocytes. Notably, UM-200 exhibits markedly improved metabolic stability compared to earlier analogs. These findings position UM-200 as a promising scaffold for developing therapeutics targeting STING-driven inflammatory and autoimmune disorders.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z